Using a multi-country preference study with 219 European patients with hidradenitis suppurativa, this study revealed that the two most important treatment attributes were effectiveness and pain reduction.

Higher levels of effectiveness, namely a 75% or 100% reduction in the abscess and inflammatory nodule count, were preferred over levels of effectiveness primarily investigated in current clinical trials of hidradenitis suppurativa (a 50% reduction).